AFos inhibits phenylephrine-mediated contractile dysfunction by altering phospholamban phosphorylation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 298, Issue 6, 2010, Pages

  Jeong, Mark Y ^a   Walker, John S ^a   Brown, R Dale ^a   Moore, Russell L ^c   Vinson, Charles S ^d   Colucci, Wilson S ^b   Long, Carlin S ^a  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

adrenergic; Activator protein 1; Hypertrophy; Myocyte

Indexed keywords

BETA GALACTOSIDE; PHOSPHOLAMBAN; PROTEIN C FOS; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ADENOVIRUS INFECTION; AFOS GENE; ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL ISOLATION; CONTROLLED STUDY; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION; HEART LEFT VENTRICLE MUSCLE; HEART VENTRICLE CONTRACTILITY; MUSCLE FUNCTION; MUSCLE GROWTH; MUSCLE HYPERTROPHY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RAT;

ADENOVIRIDAE; ANIMALS; BETA-GALACTOSIDASE; CALCIUM; CALCIUM-BINDING PROTEINS; CARDIOTONIC AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; GENES, FOS; HEART VENTRICLES; HYPERTROPHY; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PHENYLEPHRINE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTOR AP-1;

EID: 77952594690     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00937.2009     Document Type: Article

References (35)

1. Chen G, Zhou X, Nicolaou P, Rodriguez P, Song G, Mitton B, Pathak A, Zachariah A, Fan GC, Dorn GW 2nd, Kranias EG. A human polymorphism of protein phosphatase-1 inhibitor-1 is associated with attenuated contractile response of cardiomyocytes to beta-adrenergic stimulation. FASEB J 22: 1790-1796, 2008.
2. Chinenov Y, Kerppola TK. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 20: 2438-2452, 2001.
3. Everett AW, Prior G, Zak R. Equilibration of leucine between the plasma compartment and leucyl-tRNA in the heart, and turnover of cardiac myosin heavy chain. Biochem J 194: 365-368, 1981. (Pubitemid 11152286)
4. Frantz S, Fraccarollo D, Wagner H, Behr TM, Jung P, Angermann CE, Ertl G, Bauersachs J. Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res 57: 749-756, 2003. (Pubitemid 36254868)
5. Gerdes MJ, Myakishev M, Frost NA, Rishi V, Moitra J, Acharya A, Levy MR, Park SW, Glick A, Yuspa SH, Vinson C. Activator protein-1 activity regulates epithelial tumor cell identity. Cancer Res 66: 7578-7588, 2006. (Pubitemid 44289214)
6. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, Hashimoto H, Yoshino S, Matsui N, Nobunaga M. Long-term safety study of iguratimod in patients with rheumatoid arthritis. Mod Rheumatol 17: 10-16, 2007. (Pubitemid 46758764)
7. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, Hashimoto H, Yoshino S, Matsui N, Nobunaga M, Nakano S. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 17: 1-9, 2007. (Pubitemid 46758763)
8. Hilfiker-Kleiner D, Hilfiker A, Castellazzi M, Wollert KC, Trautwein C, Schunkert H, Drexler H. JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity. Cardiovasc Res 71: 108-117, 2006. (Pubitemid 43870059)
9. Hilfiker-Kleiner D, Hilfiker A, Kaminski K, Schaefer A, Park JK, Michel K, Quint A, Yaniv M, Weitzman JB, Drexler H. Lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and angiogenesis in the heart. Circulation 112: 1470-1477, 2005. (Pubitemid 41291772)
10. Jeong MY, Kinugawa K, Vinson C, Long CS. AFos dissociates cardiac myocyte hypertrophy and expression of the pathological gene program. Circulation 111: 1645-1651, 2005. (Pubitemid 40525164)
11. Johnson RS, van Lingen B, Papaioannou VE, Spiegelman BM. A null mutation at the c-jun locus causes embryonic lethality and retarded cell growth in culture. Genes Dev 7: 1309-1317, 1993.
12. Kim-Mitsuyama S, Izumi Y, Izumiya Y, Namba M, Yoshida K, Wake R, Yoshiyama M, Iwao H. Dominant-negative c-Jun inhibits rat cardiac hypertrophy induced by angiotensin II and hypertension. Gene Ther 13: 348-355, 2006. (Pubitemid 43223104)
13. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566, 1990. (Pubitemid 20176696)
14. Lindemann JP. Alpha-adrenergic stimulation of sarcolemmal protein phosphorylation and slow responses in intact myocardium. J Biol Chem 261: 4860-4867, 1986.
15. 2+-ATPase activity in guinea pig ventricles. J Biol Chem 258: 464-471, 1983.
16. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346: 1357-1365, 2002. (Pubitemid 34754608)
17. Martin AF, Rabinowitz M, Blough R, Prior G, Zak R. Measurements of half-life of rat cardiac myosin heavy chain with leucyl-tRNA used as precursor pool. J Biol Chem 252: 3422-3429, 1977. (Pubitemid 8113933)
18. Okada S, Wang ZQ, Grigoriadis AE, Wagner EF, von Ruden T. Mice lacking c-fos have normal hematopoietic stem cells but exhibit altered B-cell differentiation due to an impaired bone marrow environment. Mol Cell Biol 14: 382-390, 1994. (Pubitemid 24013099)
19. Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky E, Vinson C. A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J Biol Chem 272: 18586-18594, 1997. (Pubitemid 27318198)
20. Omura T, Yoshiyama M, Yoshida K, Nakamura Y, Kim S, Iwao H, Takeuchi K, Yoshikawa J. Dominant negative mutant of c-Jun inhibits cardiomyocyte hypertrophy induced by endothelin 1 and phenylephrine. Hypertension 39: 81-86, 2002. (Pubitemid 34098093)
21. Sande JB, Sjaastad I, Hoen IB, Bokenes J, Tonnessen T, Holt E, Lunde PK, Christensen G. Reduced level of serine(16) phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity. Cardiovasc Res 53: 382-391, 2002. (Pubitemid 34117689)
22. Satoh N, Suter TM, Liao R, Colucci WS. Chronic alpha-adrenergic receptor stimulation modulates the contractile phenotype of cardiac myocytes in vitro. Circulation 102: 2249-2254, 2000.
23. Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, Mende U, Kranias EG, MacLennan DH, Seidman JG, Seidman CE. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299: 1410-1413, 2003. (Pubitemid 36254657)
24. 2+-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol 31: 479-491, 1999.
25. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131-E136, 2002. (Pubitemid 34521026)
26. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 20: 2390-2400, 2001.
27. Stein B, Bartel S, Kokott S, Krause EG, Schlichtmann T, Schmitz W, Scholz H. Effects of isoprenaline on force of contraction, cAMP content, and phosphorylation of regulatory proteins in hearts from chronic beta-adrenergic-stimulated rats. Ann NY Acad Sci 752: 230-233, 1995.
28. Sucharov CC, Dockstader K, McKinsey TA. YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5. Mol Biol Cell 19: 4141-4153, 2008.
29. Taimor G, Schluter KD, Best P, Helmig S, Piper HM. Transcription activator protein 1 mediates α- but not β-adrenergic hypertrophic growth responses in adult cardiomyocytes. Am J Physiol Heart Circ Physiol 286: H2369-H2375, 2004.
30. Talosi L, Edes I, Kranias EG. Intracellular mechanisms mediating reversal of β-adrenergic stimulation in intact beating hearts. Am J Physiol Heart Circ Physiol 264: H791-H797, 1993.
31. Talosi L, Kranias EG. Effect of alpha-adrenergic stimulation on activation of protein kinase C and phosphorylation of proteins in intact rabbit hearts. Circ Res 70: 670-678, 1992.
32. Walker JS, Walker LA, Etter EF, Murphy RA. A dilution immunoassay to measure myosin regulatory light chain phosphorylation. Anal Biochem 284: 173-182, 2000.
33. Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF. Bone and haematopoietic defects in mice lacking c-fos. Nature 360: 741-745, 1992. (Pubitemid 23012271)
34. Wegener AD, Simmerman HK, Lindemann JP, Jones LR. Phospholamban phosphorylation in intact ventricles. Phosphorylation of serine 16 and threonine 17 in response to beta-adrenergic stimulation. J Biol Chem 264: 11468-11474, 1989.
35. Yoshiyama M, Omura T, Takeuchi K, Kim S, Shimada K, Yamagishi H, Teragaki M, Akioka K, Iwao H, Yoshikawa J. Angiotensin blockade inhibits increased JNKs, AP-1 and NF-kappa B DNA-binding activities in myocardial infarcted rats. J Mol Cell Cardiol 33: 799-810, 2001. (Pubitemid 32538992)